800.850.4306
  • Facebook
  • Twitter
  • LinkedIn
  • Facebook
  • Twitter
  • LinkedIn
  • Insights
    • News
    • Media
    • Events
  • About Us
    • Who We Are
    • Biologics Leadership
    • Careers
  • Contact
Biologics by McKesson
  • Patients
  • Providers
  • Biopharma
    • Oncology
    • Rare and Orphan Care
    • Risk-Based Care
  • Payers
  • How to Prescribe
Select Page

REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson

Dec 19, 2022 | Press Release

CARY, N.C., Dec. 19, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM...

Recent Posts

  • OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
  • Video Transcript: Risk-Based Care: Personalized care for better patient outcomes
  • Video Transcript: Risk-Based Care: Personalized care for better outcomes | Dan & Porscha
  • VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
  • Improving Oncology Patient Outcomes: The Future of Risk-Based Care

Archives

Biologics by McKesson logo

11800 Weston Parkway
Cary, NC 27513
T. 800.850.4306

 

Legal
Privacy Notice
Terms of Use
Nondiscrimination Notice

For Patients
Privacy Practices (pdf)
Patient’s Rights (pdf)

Learn more about McKesson

URAC Specialty Pharmacy accreditation seal for Biologics exp 2026ACHC Accreditation logo ACHC Accredited Oncology Logo

NASP seal denoting Biologics as a proud corporate member

Home
Patients
Providers
Payers
Biopharma
News
Careers
About Us
Leadership
Contact
Resources
How to Prescribe

© 2019 McKesson Corporation. All Rights Reserved.